Rani Therapeutics Holdings Inc (NASDAQ:RANI) experienced an 18% jump in its stock price following news that the ...

Aspect Biosystems presents preclinical data showing potential of its adrenal BTTs to restore adrenal function and treat ...

Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label ...

SOUTH SAN FRANCISCO, CA, USA I July 14, 2025 I Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human ...

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics ...

ENDO 2025 spotlights breakthrough research in PCOS, obesity, diabetes, and rare endocrine disorders and offers practical updates for daily clinical care. As the sun rises over San Francisco, ...

Full data from Phase 3 TRANSCEND study underscore potential efficacy of setmelanotide, including with prior use or concomitant use of GLP-1s - BOSTON, July 12, 2025 (GLOBE NEWSWIRE) -- Rhythm ...

These new studies are the latest examples of how our whole-transcriptome-based Afirma GRID research tool is helping to advance our collective understanding of thyroid cancer at the molecular level,” ...